Background: Indonesia faces an HIV epidemic that is in rapid transition. Injecting drug users (IDUs) are among the most heavily affected risk populations, with estimated prevalence of HIV reaching 50% or more in most parts of the country. Although Indonesia started opening methadone clinics in 2003, coverage remains low. Methods: We used the Asian Epidemic Model and Resource Needs Model to evaluate the long-term population-level preventive impact of expanding Methadone Maintenance Therapy (MMT) in West Java (43 million people). We compared intervention costs and the number of incident HIV cases in the intervention scenario with current practice to establish the cost per infection averted by expanding MMT. An extensive sensitivity analysis was performed on costs and epidemiological input, as well as on the cost-effectiveness calculation itself. Results: Our analysis shows that expanding MMT from 5% coverage now to 40% coverage in 2019 would avert approximately 2400 HIV infections, at a cost of approximately US$7000 per HIV infection averted. Sensitivity analyses demonstrate that the use of alternative assumptions does not change the study conclusions. Conclusion: Our analyses suggest that expanding MMT is cost-effective, and support government policies to make MMT widely available as an integrated component of HIV/AIDS control in West Java.
Introduction
Apart from sub-Saharan Africa, HIV epidemics are mainly concentrated among most-at-risk populations (WHO/UNAIDS, 2007) . Injecting drug users (IDUs) constitute an important risk group, estimated at 15.9 million individuals globally, of whom 3 million are HIV-infected. The size of the IDU population and the prevalence of HIV in this population have increased in the past decade (Mathers et al., 2008) .
Indonesia has significantly contributed to this increase. HIV increased considerably in Indonesia from the mid-1990s onwards, paralleling the rapid rise of opioid use. Indonesia currently faces an HIV risk behaviours (Lawrinson et al., 2008) . However, many IDUs continue to inject, and therefore remain at risk of transmitting HIV or becoming infected themselves. This situation raises questions regarding the population-level preventive impact of MMT. Do intermediate behavioural outcomes also translate into final outcomes as infections averted at the populational level? In this sense, what are the long-term effects of MMT? van den Berg, Smit, Van Brussel, Coutinho, and Prins (2007) showed that full participation in harm reduction (both MMT and NSP) programs is associated with a reduced HIV transmission in the Netherlands (van den Berg et al., 2007) , but it is questionable whether these results are also applicable to the Indonesian context. Moreover, the resource requirements for harm reduction in Asia in 2009 were estimated at $500 million and MMT accounted for a significant share of these resources (Bergenstrom et al., 2010) . Therefore, careful assessment of both the costs and effects of prevention measures is warranted to further inform decisions about whether to expand MMT to higher coverage levels.
The research question in this paper is: from the societal perspective, what are the costs and effects of expanding MMT compared with current practice? This paper is the first to address the cost-effectiveness of MMT as an HIV prevention measure in a lowincome setting. We chose a modeling design to study the effects of MMT on long-term HIV transmission at the populational level. We used the Asian Epidemic Model (AEM), a well validated and widely used HIV transmission model. Most importantly, the AEM comprises all relevant risk groups and allows behaviour to change over time (Brown & Peerapatanapokin, 2004; Saidel et al., 2003) . We describe HIV transmission in the West Java province, explore the role of IDUs, and relate this role to cost-effectiveness analysis. West Java is Indonesia's most populous province (43 million people) and has one of the highest populations of HIV-infected individuals in Indonesia.
Methods

HIV transmission model
We used the AEM (Brown & Peerapatanapokin, 2004; Saidel et al., 2003) to simulate the epidemiology of HIV among the various risk groups in West Java. Our starting point of analysis was the AEM model as fitted for West Java by AIDsina and the East-West Centre, two local specialised institutes on HIV/AIDS epidemiology and modeling that developed the model and also calculated the national HIV/AIDS projections (NAC-Indonesia, 2008b) . The parameters were varied to find the model fit as shown in Table 1 , and risk behaviour was assumed constant after 2007.
The current practice scenario assumed a coverage of MMT of 1.5% in 2008 (Sharma et al., 2009 ), extrapolated to 5% in 2010 and remaining constant thereafter. The intervention scenario assumed a similar MMT coverage till the end of 2009 followed by a linear increase to 40% in 2019, following UNAIDS recommendations (Verster, Clark, Ball, & Donoghoe, 2007) . In both scenarios, the impact of MMT was modeled through changes in the prevalence and frequency of unsafe injecting drug use (the frequency of injections and percentages of needle-sharing) and condom use among IDUs, derived from the intervention impact matrix of the Resource Needs Model (RNM) (Bollinger, Stover, & Sangrujee, 2007) (Table 2) .
To estimate the impact of our intervention scenario, we ran current practice and intervention scenarios and compared the resulting annual numbers of new infections. We performed extensive one-way sensitivity analysis on all IDU-related parameters. Additionally, to cope with uncertainty in surveillance studies, we changed (±25%) functionally related clusters of both sexual and injecting behaviour parameters and single key parameters (based on our own data search). These scenarios were again fitted with observed HIV prevalences and used for alternative costeffectiveness calculations.
Cost analysis
We also employed the RNM to estimate the cost of our intervention, and linked unit cost estimates to the number of people utilising MMT. Unit costs of MMT, from the societal perspective, were taken from Afriandi et al. (2010) , which was also conducted in West Java. To summarise the findings of Afriandi et al. (2010) , this study provides full details about the costs of MMT. MMT service delivery costs were estimated using a micro-costing approach. Data regarding service utilisation (such as attendance, methadone dosage, laboratory and other investigations, and referrals to medical services) were retrieved from the clinic's records from November 2006 to October 2007. Capital costs and other recurrent costs (such as personnel, training, and other resources used) were calculated on the basis of financial administrative data. Patient costs were estimated on the basis of a survey among 48 methadone clients. This survey included information about travel costs and travelling time, monthly income, and the average number of daily working hours. This information was combined with the average total time spent per client in the clinic. All capital costs (including training and workshops), personnel costs, methadone supply, and other supplies were included in the health care system perspective. The societal perspective also included patient costs.
The unit cost estimates ($6.70 and $2.63 per client visit for the societal and health care system, respectively, with a mean of 126 visits per client per year) were altered (±25%) in the sensitivity analysis. We ran sensitivity analysis including only costs from the health care system perspective.
Cost-effectiveness analysis
We compared costs and effects of the intervention scenarios to those of the current practice scenario. The incremental costs of the intervention scenarios were divided by their incremental effects to establish the incremental cost per HIV infection averted. We discounted both costs and effects at a 3% discount rate for both costs and effects; this value was altered to 1% and 5% for effects and costs, and to 0% for effects in our sensitivity analysis. The time horizon of this study was 10 years, and was changed to 20 years in the sensitivity analysis.
Results
The HIV epidemic in West Java and the role of injecting drug use Our model simulations show a reasonably good fit with the observed prevalence of HIV among important risk groups (Fig. 1 ). Our current practice scenario predicts that in West Java, without any change in risk behaviours, the HIV prevalence in the overall adult population will not reach 0.3% before 2020. HIV prevalence among IDUs steadily approaches approximately 50% in the period from 2010 until 2020. Although HIV prevalence among FSWs is expected to grow considerably, the MSM prevalence only grows moderately ( Fig. 1) . to decrease to 40% in 2019. Compared with current practice, 2400 undiscounted HIV infections are expected to be averted by 2020, at an undiscounted cost of US$16 million. Of these averted infections, 56% would be among IDUs, 24% among FSWs, 11% among clients, 9% among lower risk populations, and just one averted infection would be among MSM. However, to put this into perspective, in the same period there would still be 95,600 HIV infections in the overall population. Expanding MMT to 40% is expected to reduce the number of infections among IDUs by 18%, while the effect on FSWs, clients, and MSM is expected to be negligible. 8551 5313 IMPACT of intervention -no effects on condom use 8654 IMPACT of intervention -no effect on condom use, neither on prevalence of injecting drug use
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CEAs on alternative scenarios Alternative 1: PWID increased sexual risk behavior (all parameters +25% for risk behavior, −25% for protective behavior).
5580
Alternative 2: PWID decreased sexual risk behavior (all parameters −25% for risk behavior, +25% for protective behavior).
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Alternative 3: all injecting behaviors + 25% (except for additional mortality parameter Table 3 shows that, in our baseline analysis, MMT costs approximately US$7000 per HIV infection averted. We performed extensive sensitivity analysis regarding the costs, epidemiological input, and the cost-effectiveness analysis calculation itself, and all incremental cost-effectiveness ratios (ICERs) fall within a factor two of US$7000 per HIV infection averted, with one exception. When adopting the health care system perspective, the ICER equals US$2676 per infection averted. When neither effects on condom use nor effects on the prevalence of injecting drug use were modeled, the ICER increased to almost US$12,000 per infection averted.
Discussion
In this study, we analysed the cost-effectiveness of MMT and the role of injecting drug use in the West Javan HIV epidemic. Our analysis suggests that MMT costs approximately US$7000 per HIV infection averted, and we found this value to vary within a factor of two in the sensitivity analysis. The relevant question here is whether MMT in West Java is an economically attractive intervention, and would merit further investment from the Indonesian government to make the services widely available. The World Health Organisation, through its WHO-CHOICE program, defines interventions that cost less than the gross domestic product (GDP) per capita per disability-adjusted life year (DALY) averted as very cost-effective, and those with a ratio that falls between one and three times the GDP per capita as cost-effective (Torres, Baltussen, Hutubessy, Acharya, & Evans, 2003) . Assuming that one averted HIV infection equates to approximately 26 averted DALYs (Tromp & Baltussen, in press ), MMT would cost approximately US$269 per DALY averted. Given that Indonesia's GDP per capita is US$2858 (IMF, 2010), MMT can be considered very cost-effective. A comparison with other interventions is more difficult to make: MMT compares favorably to other HIV-preventive interventions, such as school-based education (Galarraga, Colchero, Wamai, & Bertozzi, 2009; Hogan, Baltussen, Hayashi, Lauer, & Salomon, 2005) , but less so to a multifaceted harm reduction program (including Needle and Syringe Programs and others) in Bangladesh (Guinness et al., 2010) . These studies have been conducted in different contexts and are therefore difficult to compare. However, our study results confirm findings from Ukraine, where expanding MMT was also found to be a cost-effective intervention (costing US$530 per quality-adjusted life year gained) (Alistar, Owens, & Brandeau, 2011) .
Our results show that expanding MMT to 40% in 2019 will avert approximately 2400 HIV infections by 2020. Strikingly, only 56% of these infections will be prevented among IDUs. Two factors are of importance: the proportion of IDUs who share needles and the impact of IDUs on the epidemic as a whole. These two factors are discussed below in more detail.
In our one-way sensitivity analysis, we found '% of IDU sharing' to be the most important IDU-related parameter affecting the cost-effectiveness estimates. This parameter, together with movement in and out of this group, more or less determines the stable equilibrium of HIV prevalence among IDUs. Because IDUs inject frequently and HIV is transmitted very effectively via needles, almost all IDUs who share needles become infected and the rapid spread of HIV among IDUs is common (for an overview, see Saidel et al., 2003) . This also implies that when the epidemic has reached equilibrium among IDUs, only those who start to share needles will be likely to acquire new infections. New needle sharers comprise a small proportion of a relatively stable cohort (in our study, the average duration of being an IDU was 8 years), especially when an intervention reduces the percentage of IDUs who share needles.
IDUs have played a significant role in the West Javan HIV epidemic, and may continue to do so in the future. The link between IDUs and FSWs is strong: in our West Java projection, 41% of IDUs reported visiting sex workers. Our West Java projection confirms the findings of Saidel et al. (2003) for a hypothetical population: despite high-risk behaviour by FSWs and their clients, their HIV prevalence remained low until the introduction of HIV among IDUs. HIV initially spread rapidly among IDUs, and provided a boost to the HIV epidemic among FSWs. Because of this strong link between IDUs and FSWs, many infections among FSWs and their clients would be averted when HIV incidence and prevalence among IDUs is reduced by MMT. Overall, our analysis suggests that the proportion of incident cases caused by injecting drug use is expected to decrease and to be replaced by infections caused by heterosexual transmission. This is an important insight, and indicates the limitations of interventions such as MMT: although they may offer value for money and are therefore worthwhile, they are only able to reduce incidence slightly (2.5% in our analysis).
Our analyses demonstrate a steady rise of HIV prevalence among MSM, yet at a relatively low level. More profound analysis of the HIV epidemic among MSM is beyond the scope of this article. Although our results appear soothing, given the MSM epidemics in Asia, HIV among MSM certainly requires further investigation, including cost-effectiveness analyses of interventions among MSM.
The present analysis has a number of limitations. First, our study was limited by the availability and quality of input parameters, especially size of population groups and MMT coverage rates. Also, we assumed that most behavioural parameters would remain constant after 2007, and neglected trends such as the increased consumption of methamphetamines, which may replace heroin use and for which MMT is not an effective treatment option. Yet our extensive sensitivity analyses showed that study conclusions are robust towards alternative assumptions on key variables, which also supports the extrapolation of our findings to epidemics other than the West Java epidemic.
Second, our analysis focused on MMT and its impact on IDUs. The evaluation of other interventions (such as the social marketing of condoms among IDUs) was beyond the scope of our study, and also impossible considering the absence of reliable cost information. Nor did we evaluate interventions targeting FSWs or MSM. We acknowledge FSWs and MSM as increasingly important risk groups (as reflected in our simulations), and we call for more research on HIV among FSWs and MSM in Indonesia, including cost-effectiveness analyses of interventions that target these risk groups.
Third, our estimates regarding the impact of MMT were based on international evidence, as summarised in the impact matrix of the RNM (Bollinger et al., 2007) , and may not necessarily reflect reality in Indonesia. However, the assumed impact compares well with evidence from pilot studies of MMT at eight sites, including Jakarta (Lawrinson et al., 2008) . In Jakarta, opiate use dropped from 2.5 ± 1.4 to 0.43 ± 1.2 daily occasions of use after three months, and to 0.51 ± 1.2 daily occasions of use after six months. Blood Borne Virus Transmission Risk Assessment Questionnaire injecting risk scores (which indicate unsafe injecting behaviour) dropped from 19.05 ± 17.9 to 5.23 ± 13.1 after three months and to 3.83 ± 9.3 after six months. Self-reported abstinence rates varied between 69 and 100% at six months. In addition, a recent international systematic review (Gowing, Farrell, Bornemann, Sullivan, & Ali, 2011) of the impact of MMT supports the RNM matrix. Because of the absence of any Indonesian data to support reductions in condom non-use and the prevalence of injecting drug use after the implementation of MMT, we ran a sensitivity analysis excluding these reductions and found that study conclusions did not change.
Fourth, the present analysis considers the role of current IDUs in HIV epidemics, but ignores the impact of recreational and former IDUs. While MMT is not indicated for these groups, they may play a role in the HIV epidemic in West Java; both populations may be important bridges to transfer HIV infections originating from injecting drug use to the general population through sexual transmission. In a recent survey from Indonesia, 44% of IDUs were classified as former IDUs, of whom 66% were HIV-seropositive (Iskandar et al., 2010) .
Fifth, our analysis is somewhat limited in scope because we did not consider antiretroviral treatment of IDUs. Treatment incurs costs and reduces the transmission of HIV; however, because only a small minority of all IDUs receives treatment, we do not expect treatment outcomes to change our study conclusions. Furthermore, our analysis did not value reductions in addiction-related crimes and risk behaviours, regular contact of IDUs with medical services, reestablishment of social and societal functioning, or collateral health effects. These aspects are difficult to measure and are seldom included in cost-effectiveness analyses.
Sixth, we present the cost-effectiveness of one intervention only, and use international cost-effectiveness thresholds to classify the interventions as very cost-effective. Ideally, all possible interventions to control HIV/AIDS in West Java should be ranked on the basis of their cost-effectiveness, and investments should be geared towards the most cost-effective interventions until the budget is exhausted.
Seventh, our analysis shows that an expansion of MMT is warranted, but it does not tell us how the expansion should be performed. IDUs are a stigmatised group, and harm reduction programs often lack political support or face legislative problems. A lack of national capacity to expand harm reduction programs, including issues of funding, has been observed throughout Southeast Asia (Sharma et al., 2009) . Expanding MMT to 40% would require full commitment from the entire public health system (staff commitment, infrastructure, materials) and political and legislative support. Therefore, to successfully expand MMT, careful consideration and continuous attention to the political and organisational challenges are needed.
In sum, our analyses suggest that MMT is a cost-effective HIV prevention measure, and support government policies to make MMT services widely available as an integrated component of HIV/AIDS control in West Java.
